Compare Novo Nordisk A/S (NVO) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs IAC/Interactivecorp — how do they compare? Novo Nordisk A/S trades at $46.23 (market cap $207.85B), while IAC/Interactivecorp trades at $40.96 (market cap $2.97B). The key difference: Novo Nordisk A/S is far larger — about 70× IAC/Interactivecorp's market cap, and Novo Nordisk A/S pays a 3.81% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals.
| NVO | PPLI | |
|---|---|---|
Market Cap | $207.85B | $2.97B |
Sector | Health | Media |
52-Week High | $63.98 | $47.62 |
52-Week Low | $35.29 | $31.52 |
Enterprise Value | $222.55B | $3.28B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
PPLI trades at $40.66, down 2.21% today, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $6.77, driven by digital growth and MGM investment gains. The company is simplifying its structure and monetizing non-core assets. Valuation ratios appear attractive with a P/E of 6.76 and P/B of 0.59, though revenue has declined from $5.2B in 2022 to $2.4B in 2025.
Outlook is mixed: low valuation and asset monetization offer upside, but declining revenue and volatile earnings pose risks. Analyst consensus is bullish with a $60.50 price target, implying 49% potential upside. Key risks include execution of restructuring and dependence on MGM performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
